The present invention discloses a method and its variations for simultaneous detection of antibodies against two or more antigens of human immunodeficiency virus (HIV) and determination of approximate time (duration) post HIV infection, thereby confirming the infection, and determination of recency of an HIV infection. The number of individuals with recently infected HIV in a given period may be further used to estimate incidence of HIV in a population.

The present application relates novel HIV-1 broadly neutralizing antibodies. The antibodies of the present invention are further characterized by their ability to bind epitopes from the Env proteins. The invention also provides light and heavy chain variable region sequences. Compositions for prophylaxis, diagnosis and treatment of HIV infection are provided.

The present invention refers to methods and compositions to prevent viral entry into cells expressing the CD169/sialoadhesin surface receptor by inhibiting the coupling of the sialyllactose molecule contained in the viral membrane gangliosides to the CD 169/sialoadhesin receptor. The invention also pertains to vaccine compositions based on dendritic cells loaded with an antigen of interest whereby the vaccine is provided together with a composition capable of preventing viral entry into cells expressing the CD169/sialoadhesin. Moreover, the invention relates to diagnostic and therapeutic compositions that can be specifically delivered to enveloped virions wherein the diagnostic/therapeutic agent is coupled to CD169/sialoadhesin.

A method for detecting a disease marker using self-amplification of a detection signal is disclosed. The method can include (a) a step of simultaneously inducing an antigen-antibody immune response and an Au particle formation reaction by reduction of Au ions in an assay solution prepared by, to a pre-assay solution in which all of an antibody or antigen for detection of a disease-specific marker, free Au ions, and adsorbed Au ions are present, adding a sample, which contains a disease-specific antigen or antibody binding specifically to the antibody or the antigen, and a reducing agent; and (b) a step of confirming the presence or absence of a disease-specific marker by a chromogenic reaction through the Au particle formation.

A method of detecting a pathogen in a sample. The pathogen from the sample is captured with at least one recognition element. The sample is introduced to a paper-based microfluidic device having spaced electrodes disposed thereon. An impedance magnitude of the sample is measured across the spaced electrodes to detect a presence of the pathogen in the sample. A related paper-based microfluidic device and system are also disclosed.

Systems include test cells with sorbent material in a T-shape and defining a first flow path for a solution and a second flow path for a sample, and a test line or test site with immobilized antigens or antibodies or other ligand binding molecules located at the junction of the T. A housing houses the sorbent material and defines a first hole adjacent an end of the first flow path for receiving the solution and a second hole adjacent an end of the second flow path for receiving the sample.

Therapeutic compositions and methods for treating HIV including identification and manipulation of particular domains associated with immunogenicity.

Monoclonal neutralizing antibodies are disclosed that specifically bind to the HIV-1 gp41 membrane-proximal external region (MPER). Also disclosed are compositions including the disclosed antibodies that specifically bind gp41, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies and compositions disclosed herein can be used for detecting the presence of HIV-1 in a biological sample, or detecting an HIV-1 infection or diagnosing AIDS in a subject. In additional, the broad neutralization breadth of the disclosed antibodies makes them ideal for treating a subject with an HIV infection. Thus, disclosed are methods of treating and/or preventing HIV infection.

This invention relates to a system and methods including their manufacturing technologies for enhanced sensing capability of one or more bioagents covering from HIV, Pathogens, virus, to cells detection. More particularly, this invention is related to HIV and pathogen diagnosis system and methods which may increase its sensitivity and may reduce the diagnosis time. Furthermore, the diagnosis system and method may be applicable to all early stage patients with various age groups, where early and accuracy in diagnosis, are required.

Described herein are substituted indazoles that may selectively bind to Hsp90, methods of using the compounds, and kits including the compounds. The compounds may include detection moieties such as fluorophores that may allow for selective detection of Hsp90 in a sample. Suitable compounds include those of formula (II): ##STR00001##